[Beta 2 agonists between the FDA, Cochrane and reality].
Mihălţan
Florin
F
Ulmeanu
Ruxandra
R
D000280:Administration, Inhalation; D000318:Adrenergic beta-Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D000420:Albuterol / Q000031:analogs & derivatives / Q000627:therapeutic use; D016208:Databases, Factual; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D000068759:Formoterol Fumarate; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D015201:Meta-Analysis as Topic; D016032:Randomized Controlled Trials as Topic; D000068299:Salmeterol Xinafoate; D014481:United States; D014486:United States Food and Drug Administration
D000318:Adrenergic beta-Agonists; D004983:Ethanolamines; D005938:Glucocorticoids; D000068299:Salmeterol Xinafoate; D000420:Albuterol; D000068759:Formoterol Fumarate